Decapeptide-12 and Vitiligo

Vitiligo is a skin condition defined by the loss of epidermal melanocytes and classified as a chronic autoimmune depigmenting skin disease. Several reasons may contribute to the presence of Vitiligo, including genetics, the self-destruction of melanocytes, cytokines, autoimmune diseases, and oxidative stress. A broad depigmentation of the skin and mucosa areas defines Vitiligo. The lack of the basic fibroblast growth factor (bFGF) is considered to play a part in the pathophysiology of Vitiligo, even though the specific etiology of the condition has not yet been discovered. 

The relationship between Vitiligo and various autoimmune disorders, such as alopecia areata, rheumatoid arthritis, type 2 diabetes mellitus, Addison’s disease, pernicious anemia, systemic lupus erythematosus, and psoriasis, has been suggested by a large number of research studies. Phototherapy, surgical techniques, immunosuppressive compounds (methotrexate, azathioprine, cyclosporine, Janus kinase inhibitors, and biologics), and topical compounds, such as glucocorticoids, calcineurin inhibitors, vitamin D, and bFGF-related Decapeptide (bFGFrP) are all methods that have been researched in conjunction with Vitiligo.

Vitiligo Research

To understand the potential efficacy and action of this compound, researchers conducted a study on 65 research models of Vitiligo and exposed to a decapeptide solution. Following the onset of exposure, the information gathered from three follow-ups was recorded.

The major purpose of this research was to establish a measure that would assess the efficiency of Decapapetide-12 based on the extent of re-pigmentation (EOR). This parameter was classified as a pronounced reaction (>75%), moderate response (50-75%), mild response (<50%), or no response at all. The grade of re-pigmentation (GOR) was recorded at each follow-up examination. The GOR ranged from 1 to 7, with grade 1 indicating no change in the depigmentation region and grade 7 indicating full re-pigmentation. After the presentation, a research model assessment (PGA) was carried out. This evaluation was designed to capture the research model’s physical reaction on a scale that ranged from no change (0% improvement) to total improvement (100% improvement). 

An examination of the data was carried out. The data is provided as either the mean plus the standard deviation (SD) or the number (%). Both the data (observations) and the observations for the percentage of re-pigmentation were on an ordinal scale (grading). 

A total of 33 research models of Vitiligo were exposed to Decapeptide-12, which accounts for 50.77% of the total group, while the remaining 32 subjects were receiving combination control substances. With a mean length of five months, the peptide was presented. The first, second, and final follow-ups were at a mean of 45 days, two months, and five months, respectively. The last follow-up was speculated to occur at that point.

At the first follow-up examination, 46% of the research models appeared to exhibit a moderate reaction, defined as 50-75% re-pigmentation. Additionally, 45% of the subjects appeared to exhibit a mild response, defined as <50% re-pigmentation. Finally, eight of the subjects, or 12%, appeared to exhibit a notable reaction (re-pigmentation of more than 75%) at the second follow-up examination. A total of 68% of research models appeared to exhibit a moderate response, and 15% exhibited a light response.

The last follow-up examination suggested that 71% (46 research models) had obtained a notable response, 18% (12 research models) appeared to have had a moderate reaction, and only 6% (four research models) seemed to have had a light response when they were evaluated. The findings also implied that three research models, or 5% of the total, did not appear to have re-pigmentation by the time the experiment was completed.

Re-pigmentation of grades 6 and 7 was speculated in more research models at the last examination compared to the first follow-up examination, indicating that the peptide presentation was successful. During each subsequent examination, the overall grade of re-pigmentation suggested signs of improvement.

Researchers may find Decapeptide-12 for sale at Core Peptides. Please note that none of the substances mentioned in this article have been approved for human and animal consumption. This article is for educational purposes only.


[i] Efficacy and safety of tacrolimus 0.1% for the treatment of facial vitiligo: a multicenter randomized, double-blinded, vehicle-controlled study. Seneschal J, Duplaine A, Maillard H, et al. J Invest Dermatol. 2021;141:1728–1734.

[ii] Clinico-epidemiological profile of patients with vitiligo: a retrospective study from a tertiary care center of North India. Mahajan VK, Vashist S, Chauhan PS, Mehta KI, Sharma V, Sharma A. Indian Dermatol Online J. 2019;10:38–44.

[iii] Advances in vitiligo: update on therapeutic targets. Feng Y, Lu Y. Front Immunol. 2022;13:986918.

[iv] Basic fibroblast growth factor and tumour necrosis factor alpha in vitiligo and other hypopigmented disorders: suggestive possible therapeutic targets. Seif El Nasr H, Shaker OG, Fawzi MM, El-Hanafi G. J Eur Acad Dermatol Venereol. 2013;27:103–108.

[v] Basic fibroblast growth factor promotes melanocyte migration via activating PI3K/Akt-Rac1-FAK-JNK and ERK signaling pathways. Shi H, Lin B, Huang Y, et al. IUBMB Life. 2016;68:735–747.

[vi] Growth defects of melanocytes in culture from vitiligo subjects are spontaneously corrected in vivo in repigmenting subjects and can be partially corrected by the addition of fibroblast-derived growth factors in vitro. Puri N, Mojamdar M, Ramaiah A. Arch Dermatol Res. 1989;281:178–184.

[vii] Basic fibroblast growth factor (bFGF) related decapeptide 0.1% solution, with tacrolimus 0.1% ointment combination therapy compared with tacrolimus 0.1% ointment monotherapy in the treatment of stable vitiligo: a phase IV, randomized 12 months study. Parsad D, Godse K, Shah B, et al. Indian Journal of Clinical and Experimental Dermatology. 2020;6:249–253.

[viii] A double blind randomized phase IV clinical trial of basic fibroblast growth factor related deca-peptide in vitiligo. Ramaiah A, Kar HK, Garg VK, Bajaj N, Gupta L, Madhava AS.

Leave a Reply

Your email address will not be published. Required fields are marked *